SK281249B6 - (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom - Google Patents

(-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom Download PDF

Info

Publication number
SK281249B6
SK281249B6 SK1257-93A SK125793A SK281249B6 SK 281249 B6 SK281249 B6 SK 281249B6 SK 125793 A SK125793 A SK 125793A SK 281249 B6 SK281249 B6 SK 281249B6
Authority
SK
Slovakia
Prior art keywords
crystalline form
oxathiolan
cis
amino
hydroxymethyl
Prior art date
Application number
SK1257-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK125793A3 (en
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK281249(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK125793A3 publication Critical patent/SK125793A3/sk
Publication of SK281249B6 publication Critical patent/SK281249B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Secondary Cells (AREA)
SK1257-93A 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom SK281249B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds
PCT/EP1992/001213 WO1992021676A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives

Publications (2)

Publication Number Publication Date
SK125793A3 SK125793A3 (en) 1994-11-09
SK281249B6 true SK281249B6 (sk) 2001-01-18

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1257-93A SK281249B6 (sk) 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom

Country Status (31)

Country Link
US (1) US5905082A (no)
EP (2) EP1099700A1 (no)
JP (1) JP2851480B2 (no)
KR (1) KR100244008B1 (no)
AP (1) AP300A (no)
AT (1) ATE212630T1 (no)
AU (2) AU656379B2 (no)
BG (1) BG60914B1 (no)
CA (2) CA2311988C (no)
CZ (1) CZ284513B6 (no)
DE (1) DE69232387T2 (no)
DK (1) DK0517145T3 (no)
ES (1) ES2171158T3 (no)
GB (1) GB9111902D0 (no)
GE (1) GEP19991834B (no)
HK (1) HK1009599A1 (no)
IE (2) IE921780A1 (no)
IL (1) IL102073A (no)
IS (2) IS1867B (no)
MX (1) MX9202619A (no)
NO (1) NO301713B1 (no)
NZ (1) NZ242981A (no)
OA (1) OA09913A (no)
PT (1) PT517145E (no)
RU (1) RU2102393C1 (no)
SG (1) SG52455A1 (no)
SK (1) SK281249B6 (no)
TW (1) TW254939B (no)
UA (1) UA41265C2 (no)
WO (1) WO1992021676A1 (no)
ZA (1) ZA924007B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2002335489B2 (en) * 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
ES2286471T3 (es) * 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1809662B1 (en) * 2004-11-10 2008-11-26 Novartis Vaccines and Diagnostics, Inc. Deamidated interferon-beta
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
DE602007009957D1 (de) * 2006-04-18 2010-12-02 Lupin Ltd Neue kristalline form von lamivudin
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
US20100324290A1 (en) * 2007-11-29 2010-12-23 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
CN101918416A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体
EP2225232B1 (en) * 2007-11-29 2012-09-26 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
US8536151B2 (en) * 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
WO2010137027A1 (en) * 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
EP2454244B1 (en) 2009-07-15 2013-06-26 Lupin Limited An improved process for preparation of efavirenz
EP2488516B1 (en) 2009-10-14 2015-04-01 Mylan Laboratories Limited Process for the preparation of lamivudine and novel salts in the manufacture thereof
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) * 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides

Also Published As

Publication number Publication date
EP0517145A1 (en) 1992-12-09
AU1881092A (en) 1993-01-08
IS1867B (is) 2003-05-02
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
IL102073A (en) 1996-05-14
US5905082A (en) 1999-05-18
CA2311988C (en) 2005-11-15
EP1099700A1 (en) 2001-05-16
IS3873A (is) 1992-12-04
WO1992021676A1 (en) 1992-12-10
IS4268A (is) 1995-02-27
BG98254A (bg) 1994-07-29
AU656379B2 (en) 1995-02-02
DE69232387D1 (de) 2002-03-14
RU2102393C1 (ru) 1998-01-20
GB9111902D0 (en) 1991-07-24
NO301713B1 (no) 1997-12-01
DK0517145T3 (da) 2002-05-06
KR100244008B1 (ko) 2000-03-02
AU1736192A (en) 1993-03-11
JPH06211848A (ja) 1994-08-02
IL102073A0 (en) 1993-01-14
CA2311988A1 (en) 1992-12-04
JP2851480B2 (ja) 1999-01-27
EP0517145B1 (en) 2002-01-30
NO922182L (no) 1992-12-04
IE921780A1 (en) 1992-12-16
CA2070230C (en) 2004-08-03
BG60914B1 (bg) 1996-06-28
UA41265C2 (uk) 2001-09-17
CA2070230A1 (en) 1992-12-04
TW254939B (no) 1995-08-21
OA09913A (en) 1994-09-15
ES2171158T3 (es) 2002-09-01
IE20020782A1 (en) 2003-04-02
KR930000511A (ko) 1993-01-15
SK125793A3 (en) 1994-11-09
GEP19991834B (en) 1999-11-05
NZ242981A (en) 1994-04-27
CZ284513B6 (cs) 1998-12-16
NO922182D0 (no) 1992-06-02
MX9202619A (es) 1992-12-01
AP300A (en) 1994-01-20
CZ261293A3 (en) 1994-04-13
ZA924007B (en) 1993-04-28
DE69232387T2 (de) 2002-09-26
PT517145E (pt) 2002-07-31
SG52455A1 (en) 1998-09-28
HK1009599A1 (en) 1999-06-04

Similar Documents

Publication Publication Date Title
SK281249B6 (sk) (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom
IE83503B1 (en) Crystalline oxathiolane derivatives
SK391091A3 (en) Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
BG60679B1 (bg) Аналози на 1,3-оксатиоланнуклеозида
US20080287378A1 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
EP1727798A1 (de) Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
CN107540710B (zh) 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
AU2008331168A1 (en) Crystalline form I of lamivudine and its preparation
KR20170078710A (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
WO2022009863A1 (ja) ベンゾイソキサゾール誘導体
KR100453301B1 (ko) 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
US20120184728A1 (en) Compound Amycolose Derivative, Method for Producing the Same, and Use of the Same
RU2252211C2 (ru) Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
CN114502550B (zh) 替加氟共晶体
EP0456514B1 (en) 2-Fluoroneplanocin A and its production
CZ2015824A3 (cs) Krystalická forma Canagliflozinu a způsob její přípravy
CN113527395A (zh) 一种腺苷的晶型及其制备方法
JP2006232671A (ja) 新規セレナゾリン誘導体
CN117466908A (zh) 腺苷受体抑制剂的晶体形式及其制备方法和用途
CN112851640A (zh) 嘧啶苯甲酰胺化合物的硫酸盐及其用途
JPS62270527A (ja) ４１８１−２物質及びその誘導体を有効成分とする抗腫瘍剤
JP2001218595A (ja) 光学活性シクロヘキセン誘導体の製造法およびその合成中間体

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20120602